Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cetirizine
Drug ID BADD_D00417
Description Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms [A175051], [A175054]. One of the most common uses for this drug is for a condition called _allergic rhinitis_. The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. Allergic rhinitis is associated with multiple missed or unproductive days at work and school, problems with sleep, and other difficulties with day to day activities for many individuals [A175057]. Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects [A175060]. Cetirizine is one of the first second-generation H1 antihistamines (SGAHs) formulated to selectively inhibit the H1 receptor without sedating effects [A175054].
Indications and Usage For the relief of symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis and the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria
Marketing Status Discontinued
ATC Code R06AE07; S01GX12
DrugBank ID DB00341
KEGG ID D07662
MeSH ID D017332
PubChem ID 2678
TTD Drug ID D0DK8V
NDC Product Code 0363-1040; 65162-003; 65162-005; 71776-024; 65015-888; 60505-4668; 55111-853; 60505-4706; 51824-076; 65162-684
Synonyms Cetirizine | (2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic Acid | Cetirizine Dihydrochloride | Dihydrochloride, Cetirizine | Virlix | Zetir | Zyrtec | Reactine | Voltric | Zirtek | Cetirizin AL | Cetirizin AZU | Cetirizin Basics | Alerlisin | Cetalerg | Ceterifug | Ceti TAD | Ceti-Puren | Cetiderm | Cetidura | Cetil von ct | CetiLich | Cetirigamma | P-071 | P 071 | P071 | Cetirlan
Chemical Information
Molecular Formula C21H25ClN2O3
CAS Registry Number 83881-51-0
SMILES C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypertension24.08.02.001--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hypertonic bladder17.10.01.003; 20.03.03.0030.000132%Not Available
Hypertrichosis23.02.04.002--
Hyperventilation19.01.02.004; 22.02.01.006--Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.000265%
Hypotension24.06.03.002--
Hypotonia17.05.02.002; 15.05.04.0080.000132%Not Available
Immune system disorder10.02.01.001--Not Available
Impaired healing08.03.02.001--Not Available
Increased appetite14.03.01.003; 08.01.09.0270.000132%Not Available
Infection11.01.08.002--Not Available
Inflammatory bowel disease07.08.01.0160.000265%Not Available
Influenza like illness08.01.03.0100.000265%
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.0020.001192%
Insulinoma16.24.02.003; 07.21.09.001; 05.08.01.0040.000052%Not Available
Intraocular pressure increased13.07.04.0020.000132%Not Available
Irritability19.04.02.013; 08.01.03.011--
Irritable bowel syndrome19.24.01.003; 07.02.04.0030.000199%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.000199%Not Available
Joint swelling15.01.02.004--Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.000596%
Libido decreased21.03.02.005; 19.08.03.001--
Lip dry07.06.01.0030.000132%Not Available
Lip oedema07.05.04.004; 23.04.01.006; 10.01.05.0040.000052%Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.000199%Not Available
Liver disorder09.01.08.0010.000199%Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 14 Pages